Advanced in Lymphofollicular Hyperplasia

Dr. Andrei R. Shustov

Hematology Oncology
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Advanced in Lymphofollicular Hyperplasia
825 Eastlake Avenue E, G3-200, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrei Shustov is a Hematologist Oncology provider in Seattle, Washington. Dr. Shustov is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shustov is currently accepting new patients.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Lymphofollicular Hyperplasia.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
German
Portuguese
Russian
Ukrainian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Premera
  • EPO
  • PPO

Locations

825 Eastlake Avenue E, G3-200, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Other
Study Drugs: High Dose Chemotherapy, Autologous Stem Cell Transplant, Romidepsin
Study Phase: Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: July 27, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: October 10, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1/Phase 2
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 7 Less Clinical Trials

96 Total Publications

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
Journal: Blood cancer journal
Published: September 05, 2024
Similar Doctors
Distinguished in Lymphofollicular Hyperplasia
Dr. Langdon L. Miller
Hematology Oncology
Distinguished in Lymphofollicular Hyperplasia
Dr. Langdon L. Miller
Hematology Oncology
3057 Perkins Ln W, 
Seattle, WA 
 (4.3 miles away)
908-906-6471
Languages Spoken:
English
See accepted insurances

Langdon Miller is a Hematologist Oncology provider in Seattle, Washington. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Lymphofollicular Hyperplasia, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Mantle Cell Lymphoma (MCL).

Distinguished in Lymphofollicular Hyperplasia
Dr. Mehrdad Jafari-Boroujerdi
Hematology Oncology | Oncology | Hematology
Distinguished in Lymphofollicular Hyperplasia
Dr. Mehrdad Jafari-Boroujerdi
Hematology Oncology | Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Farsi, German, Hindi, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Mehrdad Jafari-Boroujerdi is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Dr. Jafari-Boroujerdi is rated as a Distinguished provider by MediFind in the treatment of Lymphofollicular Hyperplasia. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), and Lymphofollicular Hyperplasia. Dr. Jafari-Boroujerdi is currently accepting new patients.

Advanced in Lymphofollicular Hyperplasia
Dr. Meaghan W. O'malley
Hematology Oncology | Oncology | Hematology
Advanced in Lymphofollicular Hyperplasia
Dr. Meaghan W. O'malley
Hematology Oncology | Oncology | Hematology

Virginia Mason Medical Center

100 Ne Gilman Blvd, 
Issaquah, WA 
 (15.1 miles away)
425-557-8000
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Meaghan O'malley is a Hematologist Oncology specialist and an Oncologist in Issaquah, Washington. Dr. O'malley is rated as an Advanced provider by MediFind in the treatment of Lymphofollicular Hyperplasia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphofollicular Hyperplasia. Dr. O'malley is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shustov's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile